Coeptis Therapeutics Holdings Inc., a biopharmaceutical company developing cell therapy platforms for cancer, autoimmune, and infectious diseases, has executed a Binding Letter of Intent for the acquisition of NexGenAI Affiliates Network, a platform developed by NexGenAI Solutions Group and its affiliates that offers AI-powered marketing software and robotic process automation (RPA) capabilities.
 
By integrating AI-powered solutions and RPA tools, Coeptis not only enhances its operational efficiency but also positions itself to leverage these advanced technologies for broader applications, creating new opportunities for growth while maintaining its primary focus on biopharmaceutical innovation.
 
NexGenAI has developed a suite of marketing tools that utilize AI and RPA to optimize campaigns, streamline workflows, and generate actionable insights. By acquiring these assets, Coeptis will bring these solutions to companies seeking to overcome marketing challenges in competitive and highly regulated sectors, particularly in the biotech and pharmaceutical industries. These tools will help companies run smarter, more efficient marketing campaigns, saving time and resources while staying compliant with strict regulations.
 
Dave Mehalick, President and CEO of Coeptis Therapeutics commented, “We are excited to integrate NexGenAI Affiliates Network and groundbreaking AI and RPA-driven tools into our offerings. In industries like biotech, pharma, and MLM, where competition is so high and regulatory challenges are complex, having advanced tools to optimize marketing, streamline operations, and drive measurable results is critical.”
 
Anshuman Dash, Lead Advisory behind the development of NexGenAI Affiliates Network commented, “The integration of NexGenAI’s innovative AI-powered marketing solutions with Coeptis Therapeutics’ forward-thinking approach marks a transformative step forward. This acquisition not only validates the cutting-edge technology we’ve developed but also aligns with Coeptis’ mission to drive innovation in highly regulated industries. Together, we aim to revolutionize marketing strategies and operational efficiencies, ultimately delivering greater value to our partners and the industries we serve.”

Other Pharma Industry Acquisitions